KP
Insider
Kush Parmar
DirectorKush Parmar (Director) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Entrada Therapeutics, Inc. (TRDA). The largest single filing was $1.8M of TRDA (200,000 sh × $8.80, as filed), executed Nov 14 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$3.6M
shares × price, as filed
Last traded
Aug 10
Filed Aug 10
Median ADV $2.8M across their filed names
Open performance→Volume by month
Buys $0
Sells $4.5M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
TRDARecent filings
TRDASALE
Entrada Therapeutics, Inc.
View filing →
$1.0M144,761 sh across 2 lots
Exec Aug 7
Filed Aug 10 · 7:54 PM ET TRDASALE Entrada Therapeutics, Inc. View filing → $795K
114,756 sh × $6.93
Exec Jul 30
Filed Aug 3 · 5:26 PM ET TRDASALE Entrada Therapeutics, Inc. View filing → $1.8M
200,000 sh × $8.80
Exec Nov 14 2025
Filed Nov 18 2025 · 5:30 PM ET TRDASALE Entrada Therapeutics, Inc. View filing → $150K
20,065 sh × $7.50
Exec Jul 9 2025
Filed Jul 11 2025 · 5:30 PM ET TRDASALE Entrada Therapeutics, Inc. View filing → $777K
112,156 sh across 4 lots
Exec Jun 27 2025
Filed Jul 1 2025 · 5:30 PM ET